nodes	percent_of_prediction	percent_of_DWPC	metapath
Orphenadrine—migraine—Prednisone—prostate cancer	0.398	1	CpDpCtD
Orphenadrine—CYP2E1—prostate cancer	0.124	0.613	CbGaD
Orphenadrine—CYP3A4—prostate cancer	0.0779	0.386	CbGaD
Orphenadrine—CYP2E1—Estrone—prostate cancer	0.0263	0.114	CbGbCtD
Orphenadrine—CYP2B6—Estrone—prostate cancer	0.0259	0.113	CbGbCtD
Orphenadrine—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0253	0.11	CbGbCtD
Orphenadrine—CYP2B6—Ethinyl Estradiol—prostate cancer	0.0231	0.101	CbGbCtD
Orphenadrine—CYP2E1—Mitoxantrone—prostate cancer	0.0156	0.068	CbGbCtD
Orphenadrine—CYP3A4—Bicalutamide—prostate cancer	0.0133	0.0578	CbGbCtD
Orphenadrine—CYP3A4—Estramustine—prostate cancer	0.0124	0.0538	CbGbCtD
Orphenadrine—CYP3A4—Flutamide—prostate cancer	0.011	0.0479	CbGbCtD
Orphenadrine—CYP3A4—Abiraterone—prostate cancer	0.011	0.0479	CbGbCtD
Orphenadrine—CYP2E1—Etoposide—prostate cancer	0.00986	0.0429	CbGbCtD
Orphenadrine—CYP3A4—Cabazitaxel—prostate cancer	0.00815	0.0354	CbGbCtD
Orphenadrine—CYP3A4—Estrone—prostate cancer	0.00797	0.0346	CbGbCtD
Orphenadrine—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0071	0.0309	CbGbCtD
Orphenadrine—CYP2B6—Doxorubicin—prostate cancer	0.00664	0.0289	CbGbCtD
Orphenadrine—CYP3A4—Conjugated Estrogens—prostate cancer	0.00521	0.0227	CbGbCtD
Orphenadrine—CYP3A4—Mitoxantrone—prostate cancer	0.00474	0.0206	CbGbCtD
Orphenadrine—CYP3A4—Estradiol—prostate cancer	0.00458	0.0199	CbGbCtD
Orphenadrine—CYP3A4—Prednisone—prostate cancer	0.00394	0.0171	CbGbCtD
Orphenadrine—CYP3A4—Etoposide—prostate cancer	0.00299	0.013	CbGbCtD
Orphenadrine—CYP3A4—Docetaxel—prostate cancer	0.00273	0.0119	CbGbCtD
Orphenadrine—GRIN2D—prostate gland—prostate cancer	0.00214	0.0936	CbGeAlD
Orphenadrine—GRIN3B—testis—prostate cancer	0.00211	0.0923	CbGeAlD
Orphenadrine—CYP3A4—Doxorubicin—prostate cancer	0.00204	0.00886	CbGbCtD
Orphenadrine—SCN9A—prostate gland—prostate cancer	0.00149	0.0653	CbGeAlD
Orphenadrine—CYP2E1—urine—prostate cancer	0.00136	0.0596	CbGeAlD
Orphenadrine—SCN4A—prostate gland—prostate cancer	0.00133	0.0583	CbGeAlD
Orphenadrine—CYP3A4—urine—prostate cancer	0.0011	0.048	CbGeAlD
Orphenadrine—GRIN2D—testis—prostate cancer	0.000941	0.0412	CbGeAlD
Orphenadrine—SCN4A—renal system—prostate cancer	0.000907	0.0397	CbGeAlD
Orphenadrine—GRIN3A—testis—prostate cancer	0.000885	0.0388	CbGeAlD
Orphenadrine—CHRM2—prostate gland—prostate cancer	0.000878	0.0385	CbGeAlD
Orphenadrine—SCN9A—testis—prostate cancer	0.000657	0.0288	CbGeAlD
Orphenadrine—KCNH2—prostate gland—prostate cancer	0.000634	0.0278	CbGeAlD
Orphenadrine—SCN4A—testis—prostate cancer	0.000586	0.0257	CbGeAlD
Orphenadrine—KCNH2—seminal vesicle—prostate cancer	0.000536	0.0235	CbGeAlD
Orphenadrine—HRH1—prostate gland—prostate cancer	0.000508	0.0223	CbGeAlD
Orphenadrine—CYP2E1—prostate gland—prostate cancer	0.000489	0.0214	CbGeAlD
Orphenadrine—SCN9A—lymph node—prostate cancer	0.000476	0.0209	CbGeAlD
Orphenadrine—Cyclizine—SULT1E1—prostate cancer	0.000475	0.12	CrCbGaD
Orphenadrine—KCNH2—renal system—prostate cancer	0.000432	0.0189	CbGeAlD
Orphenadrine—KCNH2—urethra—prostate cancer	0.000425	0.0186	CbGeAlD
Orphenadrine—CYP2E1—seminal vesicle—prostate cancer	0.000413	0.0181	CbGeAlD
Orphenadrine—Feeling abnormal—Nilutamide—prostate cancer	0.000407	0.00655	CcSEcCtD
Orphenadrine—Tachycardia—Cabazitaxel—prostate cancer	0.000406	0.00653	CcSEcCtD
Orphenadrine—Feeling abnormal—Flutamide—prostate cancer	0.000405	0.00652	CcSEcCtD
Orphenadrine—Skin disorder—Cabazitaxel—prostate cancer	0.000404	0.0065	CcSEcCtD
Orphenadrine—Pruritus—Estramustine—prostate cancer	0.000394	0.00634	CcSEcCtD
Orphenadrine—Drowsiness—Goserelin—prostate cancer	0.000389	0.00626	CcSEcCtD
Orphenadrine—Asthenia—Abiraterone—prostate cancer	0.000388	0.00624	CcSEcCtD
Orphenadrine—Constipation—Degarelix—prostate cancer	0.000377	0.00607	CcSEcCtD
Orphenadrine—Pruritus—Estrone—prostate cancer	0.000376	0.00605	CcSEcCtD
Orphenadrine—HRH1—epithelium—prostate cancer	0.000374	0.0164	CbGeAlD
Orphenadrine—Urticaria—Estradiol valerate/Dienogest—prostate cancer	0.000369	0.00593	CcSEcCtD
Orphenadrine—Feeling abnormal—Degarelix—prostate cancer	0.000363	0.00585	CcSEcCtD
Orphenadrine—SCN10A—lymph node—prostate cancer	0.000362	0.0159	CbGeAlD
Orphenadrine—Confusional state—Bicalutamide—prostate cancer	0.000359	0.00578	CcSEcCtD
Orphenadrine—Constipation—Cabazitaxel—prostate cancer	0.000355	0.00572	CcSEcCtD
Orphenadrine—CYP2B6—renal system—prostate cancer	0.000355	0.0155	CbGeAlD
Orphenadrine—Asthenia—Nilutamide—prostate cancer	0.000354	0.0057	CcSEcCtD
Orphenadrine—Vomiting—Estramustine—prostate cancer	0.000354	0.0057	CcSEcCtD
Orphenadrine—Asthenia—Flutamide—prostate cancer	0.000353	0.00568	CcSEcCtD
Orphenadrine—Dizziness—Estrone—prostate cancer	0.000352	0.00566	CcSEcCtD
Orphenadrine—Urticaria—Degarelix—prostate cancer	0.00035	0.00564	CcSEcCtD
Orphenadrine—Pruritus—Nilutamide—prostate cancer	0.000349	0.00562	CcSEcCtD
Orphenadrine—Headache—Estramustine—prostate cancer	0.000349	0.00561	CcSEcCtD
Orphenadrine—Pruritus—Flutamide—prostate cancer	0.000348	0.0056	CcSEcCtD
Orphenadrine—Skin disorder—Bicalutamide—prostate cancer	0.000346	0.00557	CcSEcCtD
Orphenadrine—Vomiting—Abiraterone—prostate cancer	0.000344	0.00553	CcSEcCtD
Orphenadrine—Feeling abnormal—Cabazitaxel—prostate cancer	0.000342	0.00551	CcSEcCtD
Orphenadrine—Hypersensitivity—Estradiol valerate/Dienogest—prostate cancer	0.000342	0.0055	CcSEcCtD
Orphenadrine—HRH1—urethra—prostate cancer	0.00034	0.0149	CbGeAlD
Orphenadrine—Vomiting—Estrone—prostate cancer	0.000338	0.00544	CcSEcCtD
Orphenadrine—Headache—Estrone—prostate cancer	0.000333	0.00536	CcSEcCtD
Orphenadrine—CYP2E1—renal system—prostate cancer	0.000333	0.0146	CbGeAlD
Orphenadrine—Asthenia—Estradiol valerate/Dienogest—prostate cancer	0.000333	0.00536	CcSEcCtD
Orphenadrine—Nausea—Estramustine—prostate cancer	0.000331	0.00532	CcSEcCtD
Orphenadrine—Pruritus—Estradiol valerate/Dienogest—prostate cancer	0.000328	0.00528	CcSEcCtD
Orphenadrine—CYP2E1—urethra—prostate cancer	0.000327	0.0143	CbGeAlD
Orphenadrine—KCNH2—bone marrow—prostate cancer	0.000327	0.0143	CbGeAlD
Orphenadrine—Dizziness—Nilutamide—prostate cancer	0.000326	0.00526	CcSEcCtD
Orphenadrine—Dizziness—Flutamide—prostate cancer	0.000325	0.00523	CcSEcCtD
Orphenadrine—Hypersensitivity—Degarelix—prostate cancer	0.000325	0.00523	CcSEcCtD
Orphenadrine—Somnolence—Bicalutamide—prostate cancer	0.000317	0.0051	CcSEcCtD
Orphenadrine—Asthenia—Degarelix—prostate cancer	0.000316	0.00509	CcSEcCtD
Orphenadrine—Nausea—Estrone—prostate cancer	0.000316	0.00508	CcSEcCtD
Orphenadrine—Vomiting—Nilutamide—prostate cancer	0.000314	0.00505	CcSEcCtD
Orphenadrine—Vomiting—Flutamide—prostate cancer	0.000313	0.00503	CcSEcCtD
Orphenadrine—Pruritus—Degarelix—prostate cancer	0.000312	0.00502	CcSEcCtD
Orphenadrine—SLC6A2—testis—prostate cancer	0.000311	0.0136	CbGeAlD
Orphenadrine—Headache—Nilutamide—prostate cancer	0.000309	0.00498	CcSEcCtD
Orphenadrine—Headache—Flutamide—prostate cancer	0.000308	0.00496	CcSEcCtD
Orphenadrine—Dizziness—Estradiol valerate/Dienogest—prostate cancer	0.000307	0.00494	CcSEcCtD
Orphenadrine—Hypersensitivity—Cabazitaxel—prostate cancer	0.000306	0.00493	CcSEcCtD
Orphenadrine—Constipation—Bicalutamide—prostate cancer	0.000305	0.00491	CcSEcCtD
Orphenadrine—Tension—Goserelin—prostate cancer	0.000298	0.0048	CcSEcCtD
Orphenadrine—Asthenia—Cabazitaxel—prostate cancer	0.000298	0.0048	CcSEcCtD
Orphenadrine—Tension—Conjugated Estrogens—prostate cancer	0.000295	0.00475	CcSEcCtD
Orphenadrine—Vomiting—Estradiol valerate/Dienogest—prostate cancer	0.000295	0.00475	CcSEcCtD
Orphenadrine—Feeling abnormal—Bicalutamide—prostate cancer	0.000294	0.00473	CcSEcCtD
Orphenadrine—Nausea—Nilutamide—prostate cancer	0.000293	0.00472	CcSEcCtD
Orphenadrine—Skin disorder—Ethinyl Estradiol—prostate cancer	0.000293	0.00471	CcSEcCtD
Orphenadrine—Nausea—Flutamide—prostate cancer	0.000292	0.0047	CcSEcCtD
Orphenadrine—Dizziness—Degarelix—prostate cancer	0.000292	0.00469	CcSEcCtD
Orphenadrine—Headache—Estradiol valerate/Dienogest—prostate cancer	0.000291	0.00468	CcSEcCtD
Orphenadrine—Drowsiness—Mitoxantrone—prostate cancer	0.000287	0.00462	CcSEcCtD
Orphenadrine—Vision blurred—Goserelin—prostate cancer	0.000286	0.00461	CcSEcCtD
Orphenadrine—Vision blurred—Conjugated Estrogens—prostate cancer	0.000284	0.00457	CcSEcCtD
Orphenadrine—Urticaria—Bicalutamide—prostate cancer	0.000283	0.00456	CcSEcCtD
Orphenadrine—Vomiting—Degarelix—prostate cancer	0.00028	0.00451	CcSEcCtD
Orphenadrine—KCNH2—testis—prostate cancer	0.000279	0.0122	CbGeAlD
Orphenadrine—Headache—Degarelix—prostate cancer	0.000276	0.00445	CcSEcCtD
Orphenadrine—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.000276	0.00444	CcSEcCtD
Orphenadrine—Dizziness—Cabazitaxel—prostate cancer	0.000275	0.00442	CcSEcCtD
Orphenadrine—Palpitations—Goserelin—prostate cancer	0.000268	0.00432	CcSEcCtD
Orphenadrine—CYP3A4—renal system—prostate cancer	0.000268	0.0117	CbGeAlD
Orphenadrine—Palpitations—Conjugated Estrogens—prostate cancer	0.000266	0.00428	CcSEcCtD
Orphenadrine—Vomiting—Cabazitaxel—prostate cancer	0.000264	0.00425	CcSEcCtD
Orphenadrine—Hypersensitivity—Bicalutamide—prostate cancer	0.000263	0.00423	CcSEcCtD
Orphenadrine—Nausea—Degarelix—prostate cancer	0.000262	0.00422	CcSEcCtD
Orphenadrine—Headache—Cabazitaxel—prostate cancer	0.00026	0.00419	CcSEcCtD
Orphenadrine—Constipation—Ethinyl Estradiol—prostate cancer	0.000258	0.00415	CcSEcCtD
Orphenadrine—Asthenia—Bicalutamide—prostate cancer	0.000256	0.00412	CcSEcCtD
Orphenadrine—Pruritus—Bicalutamide—prostate cancer	0.000252	0.00406	CcSEcCtD
Orphenadrine—Confusional state—Goserelin—prostate cancer	0.00025	0.00402	CcSEcCtD
Orphenadrine—Feeling abnormal—Ethinyl Estradiol—prostate cancer	0.000248	0.004	CcSEcCtD
Orphenadrine—Anaphylactic shock—Goserelin—prostate cancer	0.000248	0.00399	CcSEcCtD
Orphenadrine—Nausea—Cabazitaxel—prostate cancer	0.000247	0.00397	CcSEcCtD
Orphenadrine—Anaphylactic shock—Conjugated Estrogens—prostate cancer	0.000246	0.00395	CcSEcCtD
Orphenadrine—Tachycardia—Goserelin—prostate cancer	0.000242	0.0039	CcSEcCtD
Orphenadrine—Skin disorder—Goserelin—prostate cancer	0.000241	0.00388	CcSEcCtD
Orphenadrine—Tachycardia—Conjugated Estrogens—prostate cancer	0.00024	0.00386	CcSEcCtD
Orphenadrine—Urticaria—Ethinyl Estradiol—prostate cancer	0.000239	0.00385	CcSEcCtD
Orphenadrine—Skin disorder—Conjugated Estrogens—prostate cancer	0.000239	0.00384	CcSEcCtD
Orphenadrine—Tension—Estradiol—prostate cancer	0.000236	0.0038	CcSEcCtD
Orphenadrine—Dizziness—Bicalutamide—prostate cancer	0.000236	0.00379	CcSEcCtD
Orphenadrine—CYP2B6—testis—prostate cancer	0.000229	0.01	CbGeAlD
Orphenadrine—Vomiting—Bicalutamide—prostate cancer	0.000227	0.00365	CcSEcCtD
Orphenadrine—Tremor—Estradiol—prostate cancer	0.000226	0.00363	CcSEcCtD
Orphenadrine—SLC6A2—lymph node—prostate cancer	0.000226	0.00988	CbGeAlD
Orphenadrine—Aplastic anaemia—Epirubicin—prostate cancer	0.000225	0.00362	CcSEcCtD
Orphenadrine—HRH1—testis—prostate cancer	0.000224	0.00981	CbGeAlD
Orphenadrine—Headache—Bicalutamide—prostate cancer	0.000223	0.00359	CcSEcCtD
Orphenadrine—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.000222	0.00357	CcSEcCtD
Orphenadrine—Agitation—Estradiol—prostate cancer	0.000221	0.00356	CcSEcCtD
Orphenadrine—Somnolence—Goserelin—prostate cancer	0.00022	0.00355	CcSEcCtD
Orphenadrine—Somnolence—Conjugated Estrogens—prostate cancer	0.000218	0.00351	CcSEcCtD
Orphenadrine—Asthenia—Ethinyl Estradiol—prostate cancer	0.000216	0.00348	CcSEcCtD
Orphenadrine—CYP2E1—testis—prostate cancer	0.000215	0.00943	CbGeAlD
Orphenadrine—Pruritus—Ethinyl Estradiol—prostate cancer	0.000213	0.00343	CcSEcCtD
Orphenadrine—Palpitations—Estradiol—prostate cancer	0.000213	0.00343	CcSEcCtD
Orphenadrine—Constipation—Goserelin—prostate cancer	0.000212	0.00341	CcSEcCtD
Orphenadrine—Nausea—Bicalutamide—prostate cancer	0.000212	0.00341	CcSEcCtD
Orphenadrine—Vision blurred—Mitoxantrone—prostate cancer	0.000211	0.0034	CcSEcCtD
Orphenadrine—Constipation—Conjugated Estrogens—prostate cancer	0.00021	0.00338	CcSEcCtD
Orphenadrine—Aplastic anaemia—Doxorubicin—prostate cancer	0.000208	0.00335	CcSEcCtD
Orphenadrine—Dimetacrine—ACHE—prostate cancer	0.000205	0.0515	CrCbGaD
Orphenadrine—Feeling abnormal—Goserelin—prostate cancer	0.000204	0.00329	CcSEcCtD
Orphenadrine—KCNH2—lymph node—prostate cancer	0.000203	0.00887	CbGeAlD
Orphenadrine—Dizziness—Ethinyl Estradiol—prostate cancer	0.000199	0.00321	CcSEcCtD
Orphenadrine—Confusional state—Estradiol—prostate cancer	0.000198	0.00319	CcSEcCtD
Orphenadrine—Urticaria—Goserelin—prostate cancer	0.000197	0.00317	CcSEcCtD
Orphenadrine—Anaphylactic shock—Estradiol—prostate cancer	0.000197	0.00316	CcSEcCtD
Orphenadrine—Urticaria—Conjugated Estrogens—prostate cancer	0.000195	0.00314	CcSEcCtD
Orphenadrine—Tamoxifen—SULT1A1—prostate cancer	0.000193	0.0486	CrCbGaD
Orphenadrine—Tachycardia—Estradiol—prostate cancer	0.000192	0.00309	CcSEcCtD
Orphenadrine—Vomiting—Ethinyl Estradiol—prostate cancer	0.000192	0.00308	CcSEcCtD
Orphenadrine—Skin disorder—Estradiol—prostate cancer	0.000191	0.00307	CcSEcCtD
Orphenadrine—Headache—Ethinyl Estradiol—prostate cancer	0.000189	0.00304	CcSEcCtD
Orphenadrine—Confusional state—Mitoxantrone—prostate cancer	0.000185	0.00297	CcSEcCtD
Orphenadrine—Anaphylactic shock—Mitoxantrone—prostate cancer	0.000183	0.00295	CcSEcCtD
Orphenadrine—Hypersensitivity—Goserelin—prostate cancer	0.000183	0.00294	CcSEcCtD
Orphenadrine—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000181	0.00291	CcSEcCtD
Orphenadrine—Nausea—Ethinyl Estradiol—prostate cancer	0.000179	0.00288	CcSEcCtD
Orphenadrine—Tachycardia—Mitoxantrone—prostate cancer	0.000179	0.00288	CcSEcCtD
Orphenadrine—Asthenia—Goserelin—prostate cancer	0.000178	0.00286	CcSEcCtD
Orphenadrine—Skin disorder—Mitoxantrone—prostate cancer	0.000178	0.00286	CcSEcCtD
Orphenadrine—Asthenia—Conjugated Estrogens—prostate cancer	0.000176	0.00284	CcSEcCtD
Orphenadrine—Pruritus—Goserelin—prostate cancer	0.000175	0.00282	CcSEcCtD
Orphenadrine—Somnolence—Estradiol—prostate cancer	0.000175	0.00281	CcSEcCtD
Orphenadrine—Pruritus—Conjugated Estrogens—prostate cancer	0.000174	0.0028	CcSEcCtD
Orphenadrine—Constipation—Estradiol—prostate cancer	0.000168	0.00271	CcSEcCtD
Orphenadrine—Dizziness—Goserelin—prostate cancer	0.000164	0.00264	CcSEcCtD
Orphenadrine—Somnolence—Mitoxantrone—prostate cancer	0.000163	0.00262	CcSEcCtD
Orphenadrine—Dizziness—Conjugated Estrogens—prostate cancer	0.000162	0.00261	CcSEcCtD
Orphenadrine—HRH1—lymph node—prostate cancer	0.000162	0.00711	CbGeAlD
Orphenadrine—Feeling abnormal—Estradiol—prostate cancer	0.000162	0.00261	CcSEcCtD
Orphenadrine—Vomiting—Goserelin—prostate cancer	0.000158	0.00254	CcSEcCtD
Orphenadrine—Constipation—Mitoxantrone—prostate cancer	0.000157	0.00252	CcSEcCtD
Orphenadrine—Vomiting—Conjugated Estrogens—prostate cancer	0.000156	0.00251	CcSEcCtD
Orphenadrine—Urticaria—Estradiol—prostate cancer	0.000156	0.00251	CcSEcCtD
Orphenadrine—Headache—Goserelin—prostate cancer	0.000155	0.0025	CcSEcCtD
Orphenadrine—Headache—Conjugated Estrogens—prostate cancer	0.000154	0.00248	CcSEcCtD
Orphenadrine—Confusional state—Etoposide—prostate cancer	0.000154	0.00247	CcSEcCtD
Orphenadrine—Hallucination—Prednisone—prostate cancer	0.000153	0.00246	CcSEcCtD
Orphenadrine—Anaphylactic shock—Etoposide—prostate cancer	0.000152	0.00245	CcSEcCtD
Orphenadrine—Feeling abnormal—Mitoxantrone—prostate cancer	0.000151	0.00243	CcSEcCtD
Orphenadrine—Tachycardia—Etoposide—prostate cancer	0.000149	0.00239	CcSEcCtD
Orphenadrine—Skin disorder—Etoposide—prostate cancer	0.000148	0.00238	CcSEcCtD
Orphenadrine—Nausea—Goserelin—prostate cancer	0.000147	0.00237	CcSEcCtD
Orphenadrine—Nausea—Conjugated Estrogens—prostate cancer	0.000146	0.00235	CcSEcCtD
Orphenadrine—Urticaria—Mitoxantrone—prostate cancer	0.000145	0.00234	CcSEcCtD
Orphenadrine—Hypersensitivity—Estradiol—prostate cancer	0.000145	0.00233	CcSEcCtD
Orphenadrine—Vision blurred—Capecitabine—prostate cancer	0.000142	0.00228	CcSEcCtD
Orphenadrine—Asthenia—Estradiol—prostate cancer	0.000141	0.00227	CcSEcCtD
Orphenadrine—Tremor—Capecitabine—prostate cancer	0.000141	0.00227	CcSEcCtD
Orphenadrine—Pruritus—Estradiol—prostate cancer	0.000139	0.00224	CcSEcCtD
Orphenadrine—Palpitations—Docetaxel—prostate cancer	0.000137	0.00221	CcSEcCtD
Orphenadrine—Somnolence—Etoposide—prostate cancer	0.000135	0.00218	CcSEcCtD
Orphenadrine—Hypersensitivity—Mitoxantrone—prostate cancer	0.000135	0.00217	CcSEcCtD
Orphenadrine—Drowsiness—Epirubicin—prostate cancer	0.000134	0.00216	CcSEcCtD
Orphenadrine—Palpitations—Capecitabine—prostate cancer	0.000133	0.00214	CcSEcCtD
Orphenadrine—Asthenia—Mitoxantrone—prostate cancer	0.000131	0.00212	CcSEcCtD
Orphenadrine—Constipation—Etoposide—prostate cancer	0.00013	0.0021	CcSEcCtD
Orphenadrine—Dizziness—Estradiol—prostate cancer	0.00013	0.00209	CcSEcCtD
Orphenadrine—Confusional state—Docetaxel—prostate cancer	0.000128	0.00205	CcSEcCtD
Orphenadrine—Anaphylactic shock—Docetaxel—prostate cancer	0.000127	0.00204	CcSEcCtD
Orphenadrine—Vision blurred—Prednisone—prostate cancer	0.000126	0.00203	CcSEcCtD
Orphenadrine—Feeling abnormal—Etoposide—prostate cancer	0.000126	0.00202	CcSEcCtD
Orphenadrine—Vomiting—Estradiol—prostate cancer	0.000125	0.00201	CcSEcCtD
Orphenadrine—Drowsiness—Doxorubicin—prostate cancer	0.000124	0.00199	CcSEcCtD
Orphenadrine—Confusional state—Capecitabine—prostate cancer	0.000124	0.00199	CcSEcCtD
Orphenadrine—Tachycardia—Docetaxel—prostate cancer	0.000124	0.00199	CcSEcCtD
Orphenadrine—Headache—Estradiol—prostate cancer	0.000123	0.00198	CcSEcCtD
Orphenadrine—Skin disorder—Docetaxel—prostate cancer	0.000123	0.00198	CcSEcCtD
Orphenadrine—Agitation—Prednisone—prostate cancer	0.000123	0.00198	CcSEcCtD
Orphenadrine—Urticaria—Etoposide—prostate cancer	0.000121	0.00195	CcSEcCtD
Orphenadrine—Tachycardia—Capecitabine—prostate cancer	0.00012	0.00193	CcSEcCtD
Orphenadrine—Skin disorder—Capecitabine—prostate cancer	0.000119	0.00192	CcSEcCtD
Orphenadrine—Nausea—Estradiol—prostate cancer	0.000117	0.00188	CcSEcCtD
Orphenadrine—Vomiting—Mitoxantrone—prostate cancer	0.000116	0.00187	CcSEcCtD
Orphenadrine—Headache—Mitoxantrone—prostate cancer	0.000115	0.00185	CcSEcCtD
Orphenadrine—Somnolence—Docetaxel—prostate cancer	0.000113	0.00181	CcSEcCtD
Orphenadrine—Hypersensitivity—Etoposide—prostate cancer	0.000112	0.00181	CcSEcCtD
Orphenadrine—Asthenia—Etoposide—prostate cancer	0.000109	0.00176	CcSEcCtD
Orphenadrine—Anaphylactic shock—Prednisone—prostate cancer	0.000109	0.00176	CcSEcCtD
Orphenadrine—Nausea—Mitoxantrone—prostate cancer	0.000109	0.00175	CcSEcCtD
Orphenadrine—Constipation—Docetaxel—prostate cancer	0.000108	0.00174	CcSEcCtD
Orphenadrine—Warfarin—CYP2C18—prostate cancer	0.000108	0.0272	CrCbGaD
Orphenadrine—Pruritus—Etoposide—prostate cancer	0.000108	0.00173	CcSEcCtD
Orphenadrine—Tachycardia—Prednisone—prostate cancer	0.000107	0.00172	CcSEcCtD
Orphenadrine—Skin disorder—Prednisone—prostate cancer	0.000106	0.00171	CcSEcCtD
Orphenadrine—Constipation—Capecitabine—prostate cancer	0.000105	0.00169	CcSEcCtD
Orphenadrine—Bedaquiline—CYP3A4—prostate cancer	0.000105	0.0263	CrCbGaD
Orphenadrine—Feeling abnormal—Docetaxel—prostate cancer	0.000104	0.00168	CcSEcCtD
Orphenadrine—Tension—Epirubicin—prostate cancer	0.000103	0.00165	CcSEcCtD
Orphenadrine—Feeling abnormal—Capecitabine—prostate cancer	0.000101	0.00163	CcSEcCtD
Orphenadrine—Dizziness—Etoposide—prostate cancer	0.000101	0.00162	CcSEcCtD
Orphenadrine—Vision blurred—Epirubicin—prostate cancer	9.86e-05	0.00159	CcSEcCtD
Orphenadrine—Urticaria—Capecitabine—prostate cancer	9.74e-05	0.00157	CcSEcCtD
Orphenadrine—Vomiting—Etoposide—prostate cancer	9.69e-05	0.00156	CcSEcCtD
Orphenadrine—Agitation—Epirubicin—prostate cancer	9.62e-05	0.00155	CcSEcCtD
Orphenadrine—Headache—Etoposide—prostate cancer	9.54e-05	0.00154	CcSEcCtD
Orphenadrine—Tension—Doxorubicin—prostate cancer	9.5e-05	0.00153	CcSEcCtD
Orphenadrine—Constipation—Prednisone—prostate cancer	9.34e-05	0.0015	CcSEcCtD
Orphenadrine—Hypersensitivity—Docetaxel—prostate cancer	9.33e-05	0.0015	CcSEcCtD
Orphenadrine—Palpitations—Epirubicin—prostate cancer	9.25e-05	0.00149	CcSEcCtD
Orphenadrine—Vision blurred—Doxorubicin—prostate cancer	9.12e-05	0.00147	CcSEcCtD
Orphenadrine—Asthenia—Docetaxel—prostate cancer	9.08e-05	0.00146	CcSEcCtD
Orphenadrine—Nausea—Etoposide—prostate cancer	9.05e-05	0.00146	CcSEcCtD
Orphenadrine—Hypersensitivity—Capecitabine—prostate cancer	9.03e-05	0.00145	CcSEcCtD
Orphenadrine—Feeling abnormal—Prednisone—prostate cancer	9e-05	0.00145	CcSEcCtD
Orphenadrine—Pruritus—Docetaxel—prostate cancer	8.96e-05	0.00144	CcSEcCtD
Orphenadrine—Agitation—Doxorubicin—prostate cancer	8.9e-05	0.00143	CcSEcCtD
Orphenadrine—Asthenia—Capecitabine—prostate cancer	8.79e-05	0.00142	CcSEcCtD
Orphenadrine—Urticaria—Prednisone—prostate cancer	8.67e-05	0.0014	CcSEcCtD
Orphenadrine—Pruritus—Capecitabine—prostate cancer	8.67e-05	0.0014	CcSEcCtD
Orphenadrine—Confusional state—Epirubicin—prostate cancer	8.61e-05	0.00139	CcSEcCtD
Orphenadrine—Palpitations—Doxorubicin—prostate cancer	8.56e-05	0.00138	CcSEcCtD
Orphenadrine—Anaphylactic shock—Epirubicin—prostate cancer	8.54e-05	0.00137	CcSEcCtD
Orphenadrine—Dizziness—Docetaxel—prostate cancer	8.37e-05	0.00135	CcSEcCtD
Orphenadrine—Toremifene—ESR1—prostate cancer	8.37e-05	0.0211	CrCbGaD
Orphenadrine—Phenoxybenzamine—SLC22A3—prostate cancer	8.34e-05	0.021	CrCbGaD
Orphenadrine—Tachycardia—Epirubicin—prostate cancer	8.33e-05	0.00134	CcSEcCtD
Orphenadrine—Skin disorder—Epirubicin—prostate cancer	8.29e-05	0.00134	CcSEcCtD
Orphenadrine—Dizziness—Capecitabine—prostate cancer	8.11e-05	0.0013	CcSEcCtD
Orphenadrine—Vomiting—Docetaxel—prostate cancer	8.05e-05	0.0013	CcSEcCtD
Orphenadrine—Hypersensitivity—Prednisone—prostate cancer	8.04e-05	0.00129	CcSEcCtD
Orphenadrine—Confusional state—Doxorubicin—prostate cancer	7.97e-05	0.00128	CcSEcCtD
Orphenadrine—Headache—Docetaxel—prostate cancer	7.93e-05	0.00128	CcSEcCtD
Orphenadrine—Anaphylactic shock—Doxorubicin—prostate cancer	7.9e-05	0.00127	CcSEcCtD
Orphenadrine—Asthenia—Prednisone—prostate cancer	7.83e-05	0.00126	CcSEcCtD
Orphenadrine—Fluoxetine—CYP3A5—prostate cancer	7.8e-05	0.0196	CrCbGaD
Orphenadrine—Vomiting—Capecitabine—prostate cancer	7.79e-05	0.00125	CcSEcCtD
Orphenadrine—Pruritus—Prednisone—prostate cancer	7.72e-05	0.00124	CcSEcCtD
Orphenadrine—Tachycardia—Doxorubicin—prostate cancer	7.71e-05	0.00124	CcSEcCtD
Orphenadrine—Headache—Capecitabine—prostate cancer	7.68e-05	0.00124	CcSEcCtD
Orphenadrine—Skin disorder—Doxorubicin—prostate cancer	7.67e-05	0.00124	CcSEcCtD
Orphenadrine—Somnolence—Epirubicin—prostate cancer	7.59e-05	0.00122	CcSEcCtD
Orphenadrine—Nausea—Docetaxel—prostate cancer	7.52e-05	0.00121	CcSEcCtD
Orphenadrine—Chlorphenamine—SLC22A1—prostate cancer	7.39e-05	0.0186	CrCbGaD
Orphenadrine—Constipation—Epirubicin—prostate cancer	7.3e-05	0.00118	CcSEcCtD
Orphenadrine—Nausea—Capecitabine—prostate cancer	7.28e-05	0.00117	CcSEcCtD
Orphenadrine—Dizziness—Prednisone—prostate cancer	7.22e-05	0.00116	CcSEcCtD
Orphenadrine—Feeling abnormal—Epirubicin—prostate cancer	7.04e-05	0.00113	CcSEcCtD
Orphenadrine—Somnolence—Doxorubicin—prostate cancer	7.02e-05	0.00113	CcSEcCtD
Orphenadrine—Vomiting—Prednisone—prostate cancer	6.94e-05	0.00112	CcSEcCtD
Orphenadrine—Headache—Prednisone—prostate cancer	6.84e-05	0.0011	CcSEcCtD
Orphenadrine—Urticaria—Epirubicin—prostate cancer	6.78e-05	0.00109	CcSEcCtD
Orphenadrine—Constipation—Doxorubicin—prostate cancer	6.76e-05	0.00109	CcSEcCtD
Orphenadrine—Toremifene—CYP1A1—prostate cancer	6.69e-05	0.0168	CrCbGaD
Orphenadrine—Levomethadyl Acetate—CYP3A5—prostate cancer	6.66e-05	0.0168	CrCbGaD
Orphenadrine—Feeling abnormal—Doxorubicin—prostate cancer	6.51e-05	0.00105	CcSEcCtD
Orphenadrine—Nausea—Prednisone—prostate cancer	6.49e-05	0.00104	CcSEcCtD
Orphenadrine—Hypersensitivity—Epirubicin—prostate cancer	6.29e-05	0.00101	CcSEcCtD
Orphenadrine—Urticaria—Doxorubicin—prostate cancer	6.28e-05	0.00101	CcSEcCtD
Orphenadrine—Diphenhydramine—CYP2C18—prostate cancer	6.14e-05	0.0155	CrCbGaD
Orphenadrine—Levomethadyl Acetate—CYP19A1—prostate cancer	6.14e-05	0.0155	CrCbGaD
Orphenadrine—Asthenia—Epirubicin—prostate cancer	6.13e-05	0.000986	CcSEcCtD
Orphenadrine—Pruritus—Epirubicin—prostate cancer	6.04e-05	0.000972	CcSEcCtD
Orphenadrine—Phenoxybenzamine—SLC22A1—prostate cancer	5.98e-05	0.0151	CrCbGaD
Orphenadrine—Chlorphenamine—CYP3A5—prostate cancer	5.96e-05	0.015	CrCbGaD
Orphenadrine—Methadone—CYP2C18—prostate cancer	5.93e-05	0.0149	CrCbGaD
Orphenadrine—Modafinil—CYP3A5—prostate cancer	5.83e-05	0.0147	CrCbGaD
Orphenadrine—Hypersensitivity—Doxorubicin—prostate cancer	5.82e-05	0.000937	CcSEcCtD
Orphenadrine—Asthenia—Doxorubicin—prostate cancer	5.67e-05	0.000913	CcSEcCtD
Orphenadrine—Dizziness—Epirubicin—prostate cancer	5.65e-05	0.000909	CcSEcCtD
Orphenadrine—Pruritus—Doxorubicin—prostate cancer	5.59e-05	0.0009	CcSEcCtD
Orphenadrine—Tolterodine—CYP2C19—prostate cancer	5.56e-05	0.014	CrCbGaD
Orphenadrine—Vomiting—Epirubicin—prostate cancer	5.43e-05	0.000874	CcSEcCtD
Orphenadrine—Tamoxifen—ESR2—prostate cancer	5.43e-05	0.0137	CrCbGaD
Orphenadrine—Reboxetine—CYP3A4—prostate cancer	5.39e-05	0.0136	CrCbGaD
Orphenadrine—Benzatropine—CYP2C19—prostate cancer	5.36e-05	0.0135	CrCbGaD
Orphenadrine—Headache—Epirubicin—prostate cancer	5.35e-05	0.000861	CcSEcCtD
Orphenadrine—Fluoxetine—CYP2C19—prostate cancer	5.31e-05	0.0134	CrCbGaD
Orphenadrine—Imipramine—SLC22A3—prostate cancer	5.28e-05	0.0133	CrCbGaD
Orphenadrine—Dizziness—Doxorubicin—prostate cancer	5.23e-05	0.000841	CcSEcCtD
Orphenadrine—Nausea—Epirubicin—prostate cancer	5.07e-05	0.000816	CcSEcCtD
Orphenadrine—Vomiting—Doxorubicin—prostate cancer	5.02e-05	0.000809	CcSEcCtD
Orphenadrine—Diphenhydramine—SLC22A1—prostate cancer	5.02e-05	0.0126	CrCbGaD
Orphenadrine—Headache—Doxorubicin—prostate cancer	4.95e-05	0.000797	CcSEcCtD
Orphenadrine—Tamoxifen—CYP1B1—prostate cancer	4.95e-05	0.0125	CrCbGaD
Orphenadrine—Warfarin—CYP2C19—prostate cancer	4.84e-05	0.0122	CrCbGaD
Orphenadrine—Warfarin—CYP1A1—prostate cancer	4.82e-05	0.0121	CrCbGaD
Orphenadrine—Carbinoxamine—CYP2E1—prostate cancer	4.82e-05	0.0121	CrCbGaD
Orphenadrine—Carbinoxamine—CYP2C19—prostate cancer	4.77e-05	0.012	CrCbGaD
Orphenadrine—Nausea—Doxorubicin—prostate cancer	4.69e-05	0.000755	CcSEcCtD
Orphenadrine—Imipramine—CYP2C18—prostate cancer	4.64e-05	0.0117	CrCbGaD
Orphenadrine—Toremifene—CYP3A4—prostate cancer	4.27e-05	0.0108	CrCbGaD
Orphenadrine—Brompheniramine—CYP2E1—prostate cancer	4.18e-05	0.0105	CrCbGaD
Orphenadrine—Brompheniramine—CYP2C19—prostate cancer	4.14e-05	0.0104	CrCbGaD
Orphenadrine—Alimemazine—CYP3A4—prostate cancer	4.01e-05	0.0101	CrCbGaD
Orphenadrine—Modafinil—CYP2C19—prostate cancer	3.97e-05	0.00999	CrCbGaD
Orphenadrine—Tamoxifen—CYP3A5—prostate cancer	3.94e-05	0.00992	CrCbGaD
Orphenadrine—Fenoprofen—PTGS2—prostate cancer	3.94e-05	0.00992	CrCbGaD
Orphenadrine—Methadone—CYP3A5—prostate cancer	3.91e-05	0.00984	CrCbGaD
Orphenadrine—Phenoxybenzamine—ADRB2—prostate cancer	3.82e-05	0.00961	CrCbGaD
Orphenadrine—Tamoxifen—CYP2A6—prostate cancer	3.81e-05	0.00961	CrCbGaD
Orphenadrine—Imipramine—SLC22A1—prostate cancer	3.79e-05	0.00954	CrCbGaD
Orphenadrine—Cyclobenzaprine—CYP3A4—prostate cancer	3.69e-05	0.0093	CrCbGaD
Orphenadrine—Tamoxifen—CYP19A1—prostate cancer	3.63e-05	0.00915	CrCbGaD
Orphenadrine—Methadone—CYP19A1—prostate cancer	3.6e-05	0.00907	CrCbGaD
Orphenadrine—Tolterodine—CYP3A4—prostate cancer	3.54e-05	0.00891	CrCbGaD
Orphenadrine—Phenprocoumon—CYP3A4—prostate cancer	3.47e-05	0.00874	CrCbGaD
Orphenadrine—Atomoxetine—CYP2C19—prostate cancer	3.41e-05	0.00859	CrCbGaD
Orphenadrine—Fluoxetine—CYP3A4—prostate cancer	3.38e-05	0.0085	CrCbGaD
Orphenadrine—Tamoxifen—ESR1—prostate cancer	3.34e-05	0.00842	CrCbGaD
Orphenadrine—Warfarin—CYP3A4—prostate cancer	3.08e-05	0.00775	CrCbGaD
Orphenadrine—Amitriptyline—CYP3A5—prostate cancer	3.04e-05	0.00765	CrCbGaD
Orphenadrine—Carbinoxamine—CYP3A4—prostate cancer	3.04e-05	0.00765	CrCbGaD
Orphenadrine—Levomethadyl Acetate—CYP3A4—prostate cancer	2.88e-05	0.00726	CrCbGaD
Orphenadrine—Trimipramine—CYP2C19—prostate cancer	2.81e-05	0.00706	CrCbGaD
Orphenadrine—Diphenhydramine—CYP2C19—prostate cancer	2.75e-05	0.00694	CrCbGaD
Orphenadrine—Tamoxifen—CYP2E1—prostate cancer	2.71e-05	0.00682	CrCbGaD
Orphenadrine—Tamoxifen—CYP2C19—prostate cancer	2.68e-05	0.00675	CrCbGaD
Orphenadrine—Doxepin—CYP2C19—prostate cancer	2.67e-05	0.00673	CrCbGaD
Orphenadrine—Tamoxifen—CYP1A1—prostate cancer	2.67e-05	0.00673	CrCbGaD
Orphenadrine—Methadone—CYP2C19—prostate cancer	2.66e-05	0.0067	CrCbGaD
Orphenadrine—Brompheniramine—CYP3A4—prostate cancer	2.63e-05	0.00662	CrCbGaD
Orphenadrine—Chlorphenamine—CYP3A4—prostate cancer	2.58e-05	0.0065	CrCbGaD
Orphenadrine—Modafinil—CYP3A4—prostate cancer	2.52e-05	0.00635	CrCbGaD
Orphenadrine—Dextropropoxyphene—CYP3A4—prostate cancer	2.49e-05	0.00628	CrCbGaD
Orphenadrine—Promazine—CYP2C19—prostate cancer	2.38e-05	0.00598	CrCbGaD
Orphenadrine—Benzphetamine—CYP3A4—prostate cancer	2.19e-05	0.00551	CrCbGaD
Orphenadrine—Atomoxetine—CYP3A4—prostate cancer	2.17e-05	0.00546	CrCbGaD
Orphenadrine—Imipramine—CYP2E1—prostate cancer	2.1e-05	0.00529	CrCbGaD
Orphenadrine—Phenoxybenzamine—CYP3A4—prostate cancer	2.09e-05	0.00526	CrCbGaD
Orphenadrine—Amitriptyline—CYP2E1—prostate cancer	2.09e-05	0.00526	CrCbGaD
Orphenadrine—Imipramine—CYP2C19—prostate cancer	2.08e-05	0.00524	CrCbGaD
Orphenadrine—Amitriptyline—CYP2C19—prostate cancer	2.07e-05	0.00521	CrCbGaD
Orphenadrine—Trimipramine—CYP3A4—prostate cancer	1.78e-05	0.00449	CrCbGaD
Orphenadrine—Tamoxifen—CYP3A4—prostate cancer	1.71e-05	0.0043	CrCbGaD
Orphenadrine—Doxepin—CYP3A4—prostate cancer	1.7e-05	0.00428	CrCbGaD
Orphenadrine—Methadone—CYP3A4—prostate cancer	1.69e-05	0.00426	CrCbGaD
Orphenadrine—Promazine—CYP3A4—prostate cancer	1.51e-05	0.00381	CrCbGaD
Orphenadrine—Imipramine—CYP3A4—prostate cancer	1.32e-05	0.00333	CrCbGaD
Orphenadrine—Amitriptyline—CYP3A4—prostate cancer	1.31e-05	0.00331	CrCbGaD
Orphenadrine—HRH1—GPCR downstream signaling—JAK2—prostate cancer	3.02e-06	3.72e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—ADRB2—prostate cancer	3.01e-06	3.71e-05	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—GSTP1—prostate cancer	3.01e-06	3.7e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling by GPCR—MAP2K1—prostate cancer	3.01e-06	3.7e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—PDHA1—prostate cancer	2.99e-06	3.68e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—UCP3—prostate cancer	2.99e-06	3.68e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—TCN2—prostate cancer	2.99e-06	3.68e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—GSTA3—prostate cancer	2.99e-06	3.68e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling by GPCR—PIK3CD—prostate cancer	2.99e-06	3.68e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—VAV3—prostate cancer	2.98e-06	3.68e-05	CbGpPWpGaD
Orphenadrine—CHRM2—GPCR downstream signaling—JAK2—prostate cancer	2.97e-06	3.66e-05	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—COMT—prostate cancer	2.96e-06	3.65e-05	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—ITPR1—prostate cancer	2.96e-06	3.65e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling by GPCR—MAP2K1—prostate cancer	2.96e-06	3.64e-05	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—GSTP1—prostate cancer	2.95e-06	3.63e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—TGFBR2—prostate cancer	2.94e-06	3.62e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling by GPCR—PIK3CD—prostate cancer	2.94e-06	3.62e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—VAV3—prostate cancer	2.94e-06	3.62e-05	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—ITPR1—prostate cancer	2.9e-06	3.57e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—ITPR1—prostate cancer	2.9e-06	3.57e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—TGFBR2—prostate cancer	2.9e-06	3.57e-05	CbGpPWpGaD
Orphenadrine—HRH1—GPCR downstream signaling—PIK3CB—prostate cancer	2.87e-06	3.53e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—SLC22A3—prostate cancer	2.85e-06	3.51e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—HSD3B1—prostate cancer	2.85e-06	3.51e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—ITPR1—prostate cancer	2.85e-06	3.51e-05	CbGpPWpGaD
Orphenadrine—CHRM2—GPCR downstream signaling—PIK3CB—prostate cancer	2.82e-06	3.48e-05	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—TYMS—prostate cancer	2.8e-06	3.44e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—IGF1R—prostate cancer	2.77e-06	3.41e-05	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—GSTM1—prostate cancer	2.76e-06	3.4e-05	CbGpPWpGaD
Orphenadrine—HRH1—GPCR downstream signaling—CXCL8—prostate cancer	2.76e-06	3.39e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling by GPCR—JAK2—prostate cancer	2.74e-06	3.38e-05	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—TYMS—prostate cancer	2.74e-06	3.37e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—TBXAS1—prostate cancer	2.74e-06	3.37e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—GSTA4—prostate cancer	2.74e-06	3.37e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—IGF1R—prostate cancer	2.72e-06	3.35e-05	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—LPL—prostate cancer	2.71e-06	3.34e-05	CbGpPWpGaD
Orphenadrine—CHRM2—GPCR downstream signaling—CXCL8—prostate cancer	2.71e-06	3.34e-05	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—GSTM1—prostate cancer	2.71e-06	3.33e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling by GPCR—JAK2—prostate cancer	2.7e-06	3.32e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—GSTA2—prostate cancer	2.67e-06	3.28e-05	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—LPL—prostate cancer	2.66e-06	3.27e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—LPL—prostate cancer	2.65e-06	3.27e-05	CbGpPWpGaD
Orphenadrine—HRH1—GPCR downstream signaling—IL2—prostate cancer	2.63e-06	3.24e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—ABCG5—prostate cancer	2.63e-06	3.24e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—SULT1A1—prostate cancer	2.63e-06	3.24e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—PDGFRB—prostate cancer	2.63e-06	3.24e-05	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—CYP1A1—prostate cancer	2.62e-06	3.23e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—LPL—prostate cancer	2.61e-06	3.22e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling by GPCR—PIK3CB—prostate cancer	2.6e-06	3.21e-05	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—ERCC2—prostate cancer	2.6e-06	3.2e-05	CbGpPWpGaD
Orphenadrine—CHRM2—GPCR downstream signaling—IL2—prostate cancer	2.59e-06	3.19e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—PDGFRB—prostate cancer	2.59e-06	3.19e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—GSTA1—prostate cancer	2.57e-06	3.17e-05	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—CYP1A1—prostate cancer	2.57e-06	3.16e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—ITGB3—prostate cancer	2.56e-06	3.16e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling by GPCR—PIK3CB—prostate cancer	2.56e-06	3.16e-05	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—ERCC2—prostate cancer	2.55e-06	3.13e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—NAT2—prostate cancer	2.54e-06	3.13e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—HSD3B2—prostate cancer	2.54e-06	3.13e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—GSTO1—prostate cancer	2.54e-06	3.13e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—ITGB3—prostate cancer	2.52e-06	3.11e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling by GPCR—CXCL8—prostate cancer	2.5e-06	3.08e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—ERBB3—prostate cancer	2.49e-06	3.06e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—FGFR2—prostate cancer	2.48e-06	3.06e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling by GPCR—CXCL8—prostate cancer	2.46e-06	3.03e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—ERBB3—prostate cancer	2.45e-06	3.01e-05	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—MTHFR—prostate cancer	2.44e-06	3.01e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—FGFR2—prostate cancer	2.44e-06	3.01e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—PLCB2—prostate cancer	2.44e-06	3e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—CYP2C18—prostate cancer	2.44e-06	3e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—LRP2—prostate cancer	2.44e-06	3e-05	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—PPARA—prostate cancer	2.4e-06	2.95e-05	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—MTHFR—prostate cancer	2.39e-06	2.95e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling by GPCR—IL2—prostate cancer	2.39e-06	2.95e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—P4HB—prostate cancer	2.39e-06	2.94e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—TERT—prostate cancer	2.38e-06	2.93e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling by GPCR—IL2—prostate cancer	2.35e-06	2.9e-05	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—PPARA—prostate cancer	2.35e-06	2.89e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—TERT—prostate cancer	2.34e-06	2.89e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—SLC22A1—prostate cancer	2.33e-06	2.86e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—HIF1A—prostate cancer	2.28e-06	2.81e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—SULT2A1—prostate cancer	2.27e-06	2.79e-05	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—CAV1—prostate cancer	2.25e-06	2.78e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—HIF1A—prostate cancer	2.24e-06	2.76e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—MED12—prostate cancer	2.23e-06	2.75e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—LEP—prostate cancer	2.22e-06	2.74e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—GNG5—prostate cancer	2.21e-06	2.72e-05	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—CAV1—prostate cancer	2.21e-06	2.72e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—CAV1—prostate cancer	2.2e-06	2.71e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—LEP—prostate cancer	2.19e-06	2.7e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—KDR—prostate cancer	2.18e-06	2.68e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—CAV1—prostate cancer	2.17e-06	2.67e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—KDR—prostate cancer	2.14e-06	2.64e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—NCOA3—prostate cancer	2.13e-06	2.62e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—ESR1—prostate cancer	2.12e-06	2.62e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—ESR1—prostate cancer	2.09e-06	2.57e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—BAD—prostate cancer	2.07e-06	2.55e-05	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—PIK3CG—prostate cancer	2.05e-06	2.53e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—BAD—prostate cancer	2.04e-06	2.51e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—HPGDS—prostate cancer	2.03e-06	2.5e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—CYP2C19—prostate cancer	2.02e-06	2.49e-05	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—PIK3CG—prostate cancer	2.01e-06	2.48e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—PIK3CG—prostate cancer	2.01e-06	2.47e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—APC—prostate cancer	2.01e-06	2.47e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—IRS1—prostate cancer	1.98e-06	2.44e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—EGF—prostate cancer	1.98e-06	2.44e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—APC—prostate cancer	1.98e-06	2.43e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—PIK3CG—prostate cancer	1.98e-06	2.43e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—ACHE—prostate cancer	1.97e-06	2.43e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—GSTT1—prostate cancer	1.97e-06	2.43e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—IRS1—prostate cancer	1.95e-06	2.4e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—EGF—prostate cancer	1.95e-06	2.4e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—CYP2A6—prostate cancer	1.95e-06	2.4e-05	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—INS—prostate cancer	1.94e-06	2.39e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—GSK3B—prostate cancer	1.93e-06	2.37e-05	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—CREBBP—prostate cancer	1.9e-06	2.34e-05	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—INS—prostate cancer	1.9e-06	2.34e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—INS—prostate cancer	1.9e-06	2.34e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—AKR1C3—prostate cancer	1.9e-06	2.34e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—GSK3B—prostate cancer	1.9e-06	2.33e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—PRKACB—prostate cancer	1.89e-06	2.32e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—INS—prostate cancer	1.87e-06	2.3e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—CYP17A1—prostate cancer	1.87e-06	2.3e-05	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—CREBBP—prostate cancer	1.86e-06	2.3e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—CREBBP—prostate cancer	1.86e-06	2.29e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—IGF1—prostate cancer	1.84e-06	2.26e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—CREBBP—prostate cancer	1.83e-06	2.26e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling by GPCR—EGFR—prostate cancer	1.83e-06	2.25e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—IGF1—prostate cancer	1.81e-06	2.23e-05	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—PIK3CD—prostate cancer	1.8e-06	2.22e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling by GPCR—EGFR—prostate cancer	1.8e-06	2.22e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—NCOA2—prostate cancer	1.78e-06	2.19e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—MAP2K1—prostate cancer	1.78e-06	2.19e-05	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—PIK3CD—prostate cancer	1.77e-06	2.18e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—PIK3CD—prostate cancer	1.76e-06	2.17e-05	CbGpPWpGaD
Orphenadrine—HRH1—GPCR downstream signaling—PIK3CA—prostate cancer	1.75e-06	2.15e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—MAP2K1—prostate cancer	1.75e-06	2.15e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—SERPINE1—prostate cancer	1.75e-06	2.15e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—PIK3CD—prostate cancer	1.74e-06	2.14e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling by GPCR—KRAS—prostate cancer	1.73e-06	2.13e-05	CbGpPWpGaD
Orphenadrine—CHRM2—GPCR downstream signaling—PIK3CA—prostate cancer	1.72e-06	2.12e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—SERPINE1—prostate cancer	1.72e-06	2.12e-05	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—NOS3—prostate cancer	1.7e-06	2.1e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling by GPCR—KRAS—prostate cancer	1.7e-06	2.09e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.7e-06	2.09e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—FGF2—prostate cancer	1.69e-06	2.08e-05	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—NOS3—prostate cancer	1.67e-06	2.06e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—NOS3—prostate cancer	1.67e-06	2.05e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—FGF2—prostate cancer	1.66e-06	2.05e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—CYP2E1—prostate cancer	1.66e-06	2.04e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—NOS3—prostate cancer	1.64e-06	2.02e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—NQO1—prostate cancer	1.64e-06	2.02e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—JAK2—prostate cancer	1.62e-06	1.99e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—TH—prostate cancer	1.62e-06	1.99e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—JAK2—prostate cancer	1.59e-06	1.96e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling by GPCR—PIK3CA—prostate cancer	1.59e-06	1.96e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—MDM2—prostate cancer	1.58e-06	1.95e-05	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—PIK3CB—prostate cancer	1.57e-06	1.94e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.57e-06	1.93e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling by GPCR—PIK3CA—prostate cancer	1.56e-06	1.92e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—ERBB2—prostate cancer	1.56e-06	1.92e-05	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—PTGS2—prostate cancer	1.56e-06	1.92e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—MDM2—prostate cancer	1.56e-06	1.92e-05	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—PIK3CB—prostate cancer	1.54e-06	1.9e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—PIK3CB—prostate cancer	1.54e-06	1.89e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—ERBB2—prostate cancer	1.53e-06	1.89e-05	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—PTGS2—prostate cancer	1.53e-06	1.88e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—GGT1—prostate cancer	1.52e-06	1.87e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—PIK3CB—prostate cancer	1.51e-06	1.86e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—NCOA1—prostate cancer	1.5e-06	1.85e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—CXCL8—prostate cancer	1.48e-06	1.82e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.48e-06	1.82e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—CXCL8—prostate cancer	1.45e-06	1.79e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—CDKN1B—prostate cancer	1.44e-06	1.78e-05	CbGpPWpGaD
Orphenadrine—HRH1—GPCR downstream signaling—AKT1—prostate cancer	1.43e-06	1.76e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—RXRA—prostate cancer	1.43e-06	1.76e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—CDKN1B—prostate cancer	1.42e-06	1.75e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—CASP3—prostate cancer	1.41e-06	1.74e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—IL2—prostate cancer	1.41e-06	1.74e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling by GPCR—IL6—prostate cancer	1.41e-06	1.73e-05	CbGpPWpGaD
Orphenadrine—CHRM2—GPCR downstream signaling—AKT1—prostate cancer	1.41e-06	1.73e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—CASP3—prostate cancer	1.39e-06	1.71e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—IL2—prostate cancer	1.39e-06	1.71e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling by GPCR—IL6—prostate cancer	1.38e-06	1.7e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—CCND1—prostate cancer	1.38e-06	1.7e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—COMT—prostate cancer	1.37e-06	1.69e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—GSTP1—prostate cancer	1.37e-06	1.68e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—CTNNB1—prostate cancer	1.36e-06	1.68e-05	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—PTEN—prostate cancer	1.36e-06	1.67e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—CCND1—prostate cancer	1.36e-06	1.67e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—ITPR1—prostate cancer	1.34e-06	1.66e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—CTNNB1—prostate cancer	1.34e-06	1.65e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—MMP9—prostate cancer	1.34e-06	1.65e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—CDKN1A—prostate cancer	1.33e-06	1.64e-05	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—PTEN—prostate cancer	1.33e-06	1.64e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—PTEN—prostate cancer	1.33e-06	1.64e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—MMP9—prostate cancer	1.32e-06	1.62e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—CDKN1A—prostate cancer	1.31e-06	1.61e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—PTEN—prostate cancer	1.31e-06	1.61e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling by GPCR—AKT1—prostate cancer	1.3e-06	1.6e-05	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—EP300—prostate cancer	1.3e-06	1.6e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling by GPCR—AKT1—prostate cancer	1.28e-06	1.57e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—TYMS—prostate cancer	1.27e-06	1.56e-05	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—EP300—prostate cancer	1.27e-06	1.56e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—EP300—prostate cancer	1.27e-06	1.56e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—GSTM1—prostate cancer	1.26e-06	1.55e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—EP300—prostate cancer	1.25e-06	1.54e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—LPL—prostate cancer	1.23e-06	1.52e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—SRC—prostate cancer	1.23e-06	1.52e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—SRC—prostate cancer	1.21e-06	1.49e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—VEGFA—prostate cancer	1.2e-06	1.48e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.19e-06	1.47e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—STAT3—prostate cancer	1.19e-06	1.46e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—VEGFA—prostate cancer	1.18e-06	1.46e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—ERCC2—prostate cancer	1.18e-06	1.45e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—STAT3—prostate cancer	1.17e-06	1.44e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—MTHFR—prostate cancer	1.11e-06	1.37e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—MYC—prostate cancer	1.1e-06	1.36e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—TGFB1—prostate cancer	1.1e-06	1.36e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—PPARA—prostate cancer	1.09e-06	1.34e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—MYC—prostate cancer	1.09e-06	1.34e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—TGFB1—prostate cancer	1.08e-06	1.34e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—EGFR—prostate cancer	1.08e-06	1.33e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—EGFR—prostate cancer	1.06e-06	1.31e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—CAV1—prostate cancer	1.02e-06	1.26e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—KRAS—prostate cancer	1.02e-06	1.26e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—KRAS—prostate cancer	1e-06	1.24e-05	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—PIK3CA—prostate cancer	9.59e-07	1.18e-05	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—PIK3CA—prostate cancer	9.39e-07	1.16e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—PIK3CA—prostate cancer	9.38e-07	1.15e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—PIK3CG—prostate cancer	9.33e-07	1.15e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—PIK3CA—prostate cancer	9.23e-07	1.14e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—TP53—prostate cancer	9.07e-07	1.12e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—TP53—prostate cancer	8.93e-07	1.1e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—INS—prostate cancer	8.83e-07	1.09e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—CREBBP—prostate cancer	8.65e-07	1.06e-05	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—IL6—prostate cancer	8.3e-07	1.02e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—PIK3CD—prostate cancer	8.2e-07	1.01e-05	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—IL6—prostate cancer	8.17e-07	1.01e-05	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—AKT1—prostate cancer	7.83e-07	9.65e-06	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—NOS3—prostate cancer	7.74e-07	9.53e-06	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—AKT1—prostate cancer	7.67e-07	9.45e-06	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—AKT1—prostate cancer	7.66e-07	9.44e-06	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—AKT1—prostate cancer	7.54e-07	9.28e-06	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—PIK3CB—prostate cancer	7.15e-07	8.8e-06	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—PTGS2—prostate cancer	7.08e-07	8.72e-06	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—PTEN—prostate cancer	6.18e-07	7.61e-06	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—EP300—prostate cancer	5.89e-07	7.25e-06	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—PIK3CA—prostate cancer	4.36e-07	5.37e-06	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—AKT1—prostate cancer	3.56e-07	4.38e-06	CbGpPWpGaD
